Krishnan Viswanadhan

Krishnan Viswanadhan, Pharm.D has a long history of work experience in the pharmaceutical industry. Krishnan began their career in 2001 as a Post Doctoral Fellow at Rutgers University. In 2002, they joined Hoffmann-La Roche as a Group Director of Oncology Regulatory Affairs & Drug Development Team Leader, and later held the positions of Director of Regulatory Affairs & Group Leader for US Regulatory Affairs, Associate Director of Global Regulatory Affairs, Senior Program Manager of Regulatory Affairs, and Program Manager of Regulatory Affairs. In 2011, they became Vice President at Advyzom. From 2015 to 2019, they were Vice President of Business Development & Global Alliances and Executive Director of Global Project Leader at Celgene, where they led the IDHIFA (enasidenib) global project team responsible for development strategy and regulatory submission which resulted in US FDA approval in 2017, and was also the Multiple Myeloma Disease Strategy lead responsible for driving development of mulitple myeloma portfolio of assets. In 2019, they were appointed Senior Vice President of Global Cell Therapy Franchise at Bristol-Myers Squibb and Director of Board of Directors at JW Therapeutics \u836f\u660e\u5de8\u8bfa. Most recently, in 2021, they became President & Chief Operating Officer at Be Biopharma.

Krishnan Viswanadhan, Pharm.D obtained a Bachelor of Science in Pharmacy with a Minor in Economics from Rutgers University between 1995 and 2000. Krishnan then went on to receive their Doctor of Pharmacy - PharmD from Rutgers University in 2001. In 2008, they completed their Master of Business Administration - MBA from Cornell Johnson Graduate School of Management.